Suppr超能文献

口服缓释利托君作为延长静脉内宫缩抑制治疗的替代方法。

Oral sustained-release ritodrine as a substitute for prolonged intravenous tocolysis.

作者信息

Gemer O, Sassoon E, Segal S

机构信息

Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel.

出版信息

Eur J Obstet Gynecol Reprod Biol. 1994 Jun 15;55(2):109-10. doi: 10.1016/0028-2243(94)90063-9.

Abstract

Prolonged administration of intravenous ritodrine is necessary in some pregnant women with recurrent preterm labor as serum levels achieved by oral administration of ritodrine are insufficient to prevent recurrent contractions. New oral sustained-release ritodrine at 320 mg/day was given to 38 women with recurrent preterm labor. Serum levels of the drug at this dosage are considered comparable with levels achieved by i.v. treatment. The average duration of treatment was 8 days (range, 1-22). Patient tolerance was acceptable, and major maternal complications did not occur. We conclude that in selected cases, it may be possible to substitute oral sustained-release ritodrine at 320 mg/day for prolonged i.v. treatment.

摘要

对于一些复发性早产的孕妇,持续静脉输注利托君是必要的,因为口服利托君所达到的血清水平不足以预防宫缩复发。给予38例复发性早产妇女每天320毫克的新型口服缓释利托君。该剂量的药物血清水平被认为与静脉治疗所达到的水平相当。平均治疗持续时间为8天(范围1 - 22天)。患者耐受性良好,未发生严重的母体并发症。我们得出结论,在某些特定情况下,每天320毫克的口服缓释利托君有可能替代长时间的静脉治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验